Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Citicoline (also known as CDP-choline) is a compound that serves as a precursor to both choline and cytidine, which are involved in the synthesis of phospholipids in cell membranes, particularly phosphatidylcholine. Its use in dementia, including Alzheimer’s disease and vascular dementia, has been explored in several clinical studies. The rationale for its use is based on its neuroprotective properties, ability to enhance phospholipid synthesis, and potential to improve neurotransmitter function, particularly acetylcholine, which is often deficient in dementia.

Systematic reviews and meta-analyses of randomized controlled trials suggest that citicoline may have modest benefits in improving cognitive function and global clinical outcomes, particularly in patients with vascular cognitive impairment. For Alzheimer’s disease, the evidence is less robust; while some studies demonstrate improvements in memory and behavior, others show minimal or no benefit compared to placebo. The European Federation of Neurological Societies includes citicoline as a treatment option for vascular cognitive impairment, but major clinical guidelines in the US and UK do not recommend it as standard treatment for dementia due to inconsistent results and limited high-quality evidence.

Overall, citicoline is generally well-tolerated and may offer some cognitive benefits, especially in vascular forms of dementia, but its effectiveness is not definitively established, and it is not considered a first-line therapy in most clinical guidelines.

More about Citicholine
More about Dementia

Other ingredients used for Dementia

Other health conditions supported by Citicholine

Products containing Citicholine